文献速递肝病

荟萃分析:胃内球囊治疗对肥胖患者非酒精性脂肪性肝病相关参数的影响

Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity.
PubMed 文献 · Aliment Pharmacol Ther · 2023-11-20

该荟萃分析纳入19项研究共911例患者,评估胃内球囊对非酒精性脂肪性肝病相关指标的影响。结果显示胃内球囊可改善NAFLD活动度评分、ALT、肝脏体积和肝脏脂肪变,并显著降低体重、BMI、糖化血红蛋白和HOMA-IR。作者认为胃内球囊可能在弥补NAFLD管理治疗缺口方面发挥重要作用。

要点

  • 胃内球囊可降低NAFLD活动度评分(均差-3.0)。
  • 胃内球囊可降低ALT(均差-10.40 U/L)和肝脏脂肪变(均差-37.76 dB/m)。
  • 胃内球囊可降低体重、BMI、糖化血红蛋白和HOMA-IR。

核心结论

  • 胃内球囊可能在弥补NAFLD管理治疗缺口方面发挥重要作用。

研究设计与样本

  • 荟萃分析,检索MEDLINE(PubMed)和EMBASE从建库至2022年9月,纳入19项研究共911例患者,包括对照和非对照研究。

主要发现

  • 胃内球囊对NAFLD活动度评分的均差为-3.0(95%CI:-2.41至-3.59)。
  • 胃内球囊对ALT的均差为-10.40 U/L(95%CI:-7.31至-13.49)。
  • 胃内球囊对肝脏体积的均差为-397.9(95%CI:-212.78至1008.58)。
  • 胃内球囊对肝脏脂肪变的均差为-37.76 dB/m(95%CI:-21.59至-53.92)。
  • 非肝脏相关结局中,体重、BMI、糖化血红蛋白和HOMA-IR均显著降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy -a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established. AIM: To evaluate the effect of IGB as a treatment option in NAFLD. METHODS: We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver-related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non-comparative studies; primary outcomes were liver-related NAFLD surrogates. RESULTS: We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): -3.0 [95% CI: -2.41 to -3.59], ALT: MD: -10.40 U/L [95% CI: -7.31 to -13.49], liver volume: MD -397.9 [95% CI: -212.78 to 1008.58] and liver steatosis: MD: -37.76 dB/m [95% CI: -21.59 to -53.92]. There were significant reductions in non-liver-related outcomes of body weight, BMI, glycated haemoglobin and HOMA-IR. CONCLUSION: Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Aoko O, Maharaj T, Boland F, et al. Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity. Aliment Pharmacol Ther. 2023. PMID: 37986213. doi:10.1111/apt.17805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。